Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia
Clinical trial NCT02232386 · COMPLETED
Trial details
- NCT number
- NCT02232386
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-02
- Primary completion
- 2018-04-01
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.